The evidence shows more aggressive and resistant HER-2-positive BC with PI3K mutations: In NeoALTTO [54], GeparSixto [55], and Neosphere [56] studies, PI3K mutations were linked to low rates of pCR and APHINITY study (adjuvant setting). Here, ERBB2 is linked to breast cancer.